ライフサイエンスコーパス: thrombopoietin receptor

1 at from mice lacking c-Mpl (c-Mpl(-/-)), the thrombopoietin receptor.

2 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu

3 The thrombopoietin receptor agonist eltrombopag has been sho

4 The oral thrombopoietin receptor agonist eltrombopag is approved

5 Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease lab

6 The thrombopoietin receptor agonist romiplostim could be an

7 Romiplostim is a thrombopoietin receptor agonist that increases platelet

8 Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new opti

9 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g

10 Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet coun

11 We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in i

12 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or

13 Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombop

14 Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombop

15 immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi

16 The effects of eltrombopag, a thrombopoietin-receptor agonist, on platelet function in

17 Eltrombopag is an oral thrombopoietin-receptor agonist.

18 Thrombopoietin receptor agonists (eltrombopag; romiplost

19 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo

20 efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l

21 Thrombopoietin receptor agonists are reported to increas

22 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation

23 Tier 1 options (rituximab, thrombopoietin receptor agonists, low-dose corticosteroi

24 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen

25 PURPOSE OF REVIEW: Thrombopoietin-receptor agonists (TPO-RAs) have been app

26 Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effecti

27 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy

28 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media

29 ies of small peptides that bind to the human thrombopoietin receptor and compete with the binding of

30 More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id

31 wn decreased megakaryocyte expression of the thrombopoietin receptor (c-mpl) in patients with polycyt

32 Here we describe a deletion mutant of the thrombopoietin receptor (c-mpl) that has completely lost

33 ematopoietic growth factors that bind to the thrombopoietin receptor, c-Mpl.

34 A thrombopoietin receptor derivative that brings the proli

35 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex

36 d to express a conditional derivative of the thrombopoietin receptor (F36Vmpl).

37 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with

38 al 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL).

39 a p.Lys39Asn amino acid substitution of the thrombopoietin receptor gene (p = 1.5 x 10(-11)).

40 a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of

41 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial

42 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a

43 lation of proteins and the expression of the thrombopoietin receptor in platelets from patients with

44 resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin

45 expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re

46 Reduced expression of the thrombopoietin receptor MpI is characteristic of polycyt

47 However, expression of the platelet thrombopoietin receptor MpI was markedly reduced or abse

48 Endocytosis of the thrombopoietin receptor Mpl was impaired in Dnm2-null pl

49 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect

50 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity

51 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec

52 Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryo

53 We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD

54 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin re

55 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw

56 a marked reduction in the expression of the thrombopoietin receptor, Mpl, in polycythemia vera (PV)

57 The thrombopoietin receptor, Mpl, is a member of the cytokin

58 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept

59 telets, and their precursors all express the thrombopoietin receptor, Mpl, on their cell surface.

60 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru

61 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu

62 miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation

63 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream

64 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap

65 ts before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9).

66 Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surfac

67 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept

68 In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQ

69 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre

70 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec

71 genic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL).

72 omerize with several other tagged receptors (thrombopoietin receptor, transforming growth factor beta

73 Although the thrombopoietin receptor was discovered in 1991 and throm

74 this idea, the signaling domain of Mpl (the thrombopoietin receptor) was targeted to the plasma memb